“Chronic hepatitis B ” AND “tenofovir”
Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs. Kumada H, Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Hepatol Res . 2016 Nov 15. doi: 10.1111/hepr.12842.
位置: 8600 Rockville Pike, Bethesda, MD

Once-daily tenofovir disoproxil fumarate in treatment …

Tenofovir disoproxil fumarate reduces the risk of progression in liver fibrosis in patients with chronic hepatitis B and minimally raised ALT, but its effect on necroinflammation is non-significant. TORCH-B is a multicentre, double-blind, placebo-controlled, parallel-group

Hepatitis B virus resistance to tenofovir:
Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection.There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well

Virologic breakthrough in a patient with chronic hepatitis …

 · Tenofovir disoproxil fumarate (TDF) is widely used to treat hepatitis B virus (HBV) patients in the USA and Europe. No confirmed report of resistance selection during treatment with TDF in treatment-naïve and nucleoside/nucleotide analog-treated chronic hepatitis B patients has yet …

Tenofovir versus Placebo to Prevent Perinatal …

Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016;374: 2324-2334. Free Full Text Web of Science Medline Google Scholar 14.

Tenofovir for Hepatitis B Suppression
Currently, tenofovir is one of four primary drugs used to help treatment-naïve Hepatitis B patients – although ongoing trials are investigating many new substances and drug combinations. The four drugs used as a first-line treatment for Hepatitis B include:

Safety and efficacy of stopping tenofovir disoproxil …

DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018; ( …

Tenofovir for patients with lamivudine‐resistant …

Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy † ‡ Florian van Bömmel Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité—Campus Virchow‐Klinikum; Universitätsmedizin Berlin, Berlin, Germany

HIV/Hepatitis B Drug, Tenofovir, May Cause Kidney and …

 · HIV/Hepatitis B Drug, Tenofovir, May Cause Kidney and Bone Damage: James Scott Farrin Ready to Fight for Victims Read full article August 6, 2020, 10:18 AM · 3 min read The Law Offices of James Scott Farrin is ready to take on cases involving users of HIV

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen …

TY – JOUR T1 – Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA AU – Chan, Henry L.Y. AU – Chan, Chi Kuen AU – Hui, Aric Josun AU – Chan

Comparison of tenofovir and entecavir on the risk of …

Objective The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcomes has not been clarified thus far. Therefore, we aimed to compare TDF and ETV on the risk of HCC

Tenofovir Alone Versus Tenofovir With Emtricitabine to …

Tenofovir is an anti-viral drug approved for use in patients with HIV infection. In small studies in patients infected with both HIV and hepatitis B, tenofovir lowered the level of hepatitis B virus in the blood, with no viral resistance reported when used for up to 5 years.

Randomized prospective study evaluating tenofovir …

 · Background Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under

Efficacy of tenofovir disoproxil fumarate at 240 weeks …

Chronic hepatitis B (CHB) patients with high pretreatment viral load (HVL) represent a clinical challenge. Higher levels of hepatitis B virus (HBV) DNA are associated with an increased risk for hepatocellular carcinoma (HCC) and cirrhosis. 1 In addition, available evidence suggests that CHB patients with HVL are less likely to respond to interferon (IFN)‐based regimens than those with lower

Tenofovir vs lamivudine for the prevention of …

The anti-CD20 monoclonal antibody rituximab, together with anthracycline, in hepatitis B surface antigen (HBsAg) healthy carriers affected by non-Hodgkin lymphoma (NHL) increases hepatitis B virus (HBV) reactivation risk. 1 Oral primary antiviral prophylaxis (PAVP) is a common strategy in this setting. 2-4 Lamivudine (LAM) has shown to be effective. 5 HBsAg-seropositive patients undergoing R

Overview
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B. Is this guidance up to date? We reviewed the evidence in October 2011.We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Erratum: Effects of tenofovir disoproxil fumarate in hepatitis B e …

Erratum: Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA (Gastroenterology (2014) 146 (1240-1248)) Henry L.Y. Chan, Chi Kuen Chan, Aric Josun